Over time, consistent therapy may support steady weight loss, improved energy, better metabolic balance, and long-term body composition changes when combined with healthy lifestyle habits
Most of retatrutide's effects come from reducing fat mass, likely because it helps people eat less food for longer periods compared to similar medications
Despite this activity, GSPT1 degradation represents a promising potential therapeutic strategy, since GSPT1 dysregulation or increased expression is associated with multiple cancers
Fewer cravings, steadier energy, and smoother blood sugar after you eat
Gallbladder In the SCALE-trial, high-dose liraglutide for the treatment of obesity was associated with an increased risk of gallbladder events compared to placebo (2.5% versus 1.0% of patients, respectively) (84)
Dual-agonist medications like tirzepatide (Mounjaro) added GIP receptor activation to the equation, resulting in improved outcomes for many patients